Is target-based drug discovery efficient? Discovery and “off-target” mechanisms of all drugs

A Sadri - Journal of medicinal chemistry, 2023 - ACS Publications
Target-based drug discovery is the dominant paradigm of drug discovery; however, a
comprehensive evaluation of its real-world efficiency is lacking. Here, a manual systematic …

[HTML][HTML] The Role of Vortioxetine in the Treatment of Depressive Symptoms in General Hospital Psychiatry: A Case-Series and PRISMA-Compliant Systematic Review …

F Weiss, B Pacciardi, G D'Alessandro… - Journal of Clinical …, 2024 - mdpi.com
Depressive symptoms are a customary finding in hospitalized patients, particularly those
who are undergoing long hospitalizations, underwent major surgical procedures or suffer …

Stereospecific Synthesis of Highly Substituted Piperazines via an One-Pot Three Component Ring-Opening Cyclization from N-Activated Aziridines, Anilines, and …

N Chauhan, S Pradhan, MK Ghorai - The Journal of Organic …, 2018 - ACS Publications
A simple and efficient one-pot three-component synthetic route to highly substituted and
functionalizable piperazines in high yields with excellent stereoselectivity (de, ee> 99%) is …

[HTML][HTML] Potential Effect of Vortioxetine on Restless Leg Syndrome

YH Alıcı, MK Kumcu - Clinical Psychopharmacology and …, 2023 - ncbi.nlm.nih.gov
Restless legs syndrome (RLS) is a chronic progressive movement disorder characterized by
abnormal sensations, especially at rest and at night, as the need and urge to move the lower …

The Discovery/Development Transition

CM Cimarusti, DR Kronenthal - Early Drug Development …, 2018 - Wiley Online Library
This chapter focuses on the conviction that minimizing the time to the first dose in man (FIM)
is an important competitive advantage during drug development. The time from the first …

Vortioxetine and Early Drug Development Considerations at the Interface of R&D

M Jørgensen, K Christensen, M Juhl… - … Candidate to the …, 2018 - Wiley Online Library
Summary Vortioxetine (Lu AA21004, 1‐[2‐(2, 4‐dimethylphenylsulfanyl) phenyl] piperazine,
Brintellix® or Trintellix®) is a multimodal serotonergic antidepressant that was approved by …